Free Trial
NASDAQ:LUNG

Pulmonx Q1 2025 Earnings Report

Pulmonx logo
$4.52 -0.27 (-5.64%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$4.53 +0.01 (+0.11%)
As of 04/17/2025 04:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pulmonx EPS Results

Actual EPS
N/A
Consensus EPS
-$0.37
Beat/Miss
N/A
One Year Ago EPS
N/A

Pulmonx Revenue Results

Actual Revenue
N/A
Expected Revenue
$22.03 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pulmonx Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, April 30, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Pulmonx Earnings Headlines

What to do with your collapsing portfolio…
There might be only one way to save your retirement in this volatile time. After watching investors lose $6 trillion in market cap in a matter of DAYS... And after seeing businesses bleeding dry as trade tensions spiral out of control... What the acclaimed “Market Wizard” Larry Benedict — who beat the market by 103% during the 2008 crash — is about to reveal could not only save your retirement from Trump's tariffs…
Pulmonx initiated with a Buy at D. Boral Capital
Lake Street Keeps Their Buy Rating on Pulmonx (LUNG)
Lake Street Keeps Their Buy Rating on Pulmonx (LUNG)
See More Pulmonx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pulmonx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulmonx and other key companies, straight to your email.

About Pulmonx

Pulmonx (NASDAQ:LUNG), a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

View Pulmonx Profile

More Earnings Resources from MarketBeat